€20.02
2.64% day before yesterday
Xetra, Dec 06, 05:39 pm CET
ISIN
DE000BAY0017
Symbol
BAYN
Sector
Industry

Bayer Stock price

€20.02
-3.93 16.41% 1M
-8.37 29.49% 6M
-13.62 40.48% YTD
-12.38 38.21% 1Y
-24.57 55.11% 3Y
-49.17 71.07% 5Y
-99.19 83.21% 10Y
Xetra, Closing price Fri, Dec 06 2024
+0.52 2.64%
ISIN
DE000BAY0017
Symbol
BAYN
Sector
Industry

Key metrics

Market capitalization €19.66b
Enterprise Value €56.34b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 13.89
EV/Sales (TTM) EV/Sales 1.21
P/S ratio (TTM) P/S ratio 0.42
P/B ratio (TTM) P/B ratio 0.64
Dividend yield 0.55%
Last dividend (FY23) €0.11
Revenue growth (TTM) Revenue growth -2.17%
Revenue (TTM) Revenue €46.74b
EBIT (operating result TTM) EBIT €6.97b
Free Cash Flow (TTM) Free Cash Flow €4.06b
Cash position €4.62b
EPS (TTM) EPS €-0.90
P/E forward 8.56
P/S forward 0.42
EV/Sales forward 1.21
Show more

Create a Free Account to create an Bayer alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Bayer Stock Analysis

Analyst Opinions

20 Analysts have issued a Bayer forecast:

4x Buy
20%
16x Hold
80%

Analyst Opinions

20 Analysts have issued a Bayer forecast:

Buy
20%
Hold
80%

Financial data from Bayer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
46,739 46,739
2% 2%
100%
- Direct Costs 20,033 20,033
0% 0%
43%
26,706 26,706
4% 4%
57%
- Selling and Administrative Expenses 10,041 10,041
11% 11%
21%
- Research and Development Expense 5,554 5,554
6% 6%
12%
11,111 11,111
5% 5%
24%
- Depreciation and Amortization 4,139 4,139
11% 11%
9%
EBIT (Operating Income) EBIT 6,972 6,972
3% 3%
15%
Net Profit -880 -880
76% 76%
-2%

In millions EUR.

Don't miss a Thing! We will send you all news about Bayer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bayer Stock News

Neutral
Seeking Alpha
one day ago
Bayer's stock has declined below €20, with Q3/24 results showing a 3.6% sales decrease and a 29.8% EBITDA drop, mainly due to currency effects. Crop Science sales fell 9.1% YoY, and Pharmaceuticals saw mixed results with Nubeqa and Kerendia growing, but Xarelto declining 23.8% due to generics. Bayer's strategic transformation under CEO Bill Anderson aims to decentralize decision-making, but lit...
Neutral
Business Wire
6 days ago
CHICAGO--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will showcase these advancements at the 2024 Radiological Society of North America (RSNA) Annual Meeting taking place from December 1-5, 2024, in Chicago. Bayer announced seven collaboration agreements...
Neutral
GlobeNewsWire
9 days ago
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Watermelon Seeds Market Size, Share & Trends Analysis Report by Type (Raw, Roasted, Dried), Distribution Channel, Region and Segment Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The global watermelon seeds market size is expected to reach USD 995.4 million by 2030, registering a CAGR of 5.8% from 2025 to 2030.
More Bayer News

Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Head office Germany
CEO William Anderson
Employees 99,723
Founded 1863
Website www.bayer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today